Picture of Inspiration Healthcare logo

IHC — Inspiration Healthcare News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

UK's Inspiration Healthcare H1 underlying revenue rises on neonatal ventilation segment

UK's Inspiration Healthcare H1 underlying revenue rises on neonatal ventilation segment


Overview

  • UK neonatal device maker's H1 revenue fell due to prior year one-off export orders

  • Underlying H1 revenue rose 26% excluding last year's one-off export orders

  • Adjusted EBITDA was stable, while operating profit rose on non-recurring credit


Outlook

  • Company expects FY27 revenue of at least £43 mln

  • Company expects positive momentum to continue into FY28

  • Planned launch of proprietary consumables in Q4 FY27 expected to support future growth


Result Drivers

  • NEONATAL VENTILATION - Co said strong momentum in neonatal ventilation portfolio drove underlying growth

  • SLE SALES - SLE product sales rose, with notable gains in capital equipment and service revenues

  • INFUSION THERAPIES RECOVERY - Co said recovery in Infusion Therapies sales contributed to distribution revenue growth


Company press release: ID:nRSa5055Aa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Adjusted EBITDA

GBP 1.20 mln

H1 Gross Margin

41.90%

H1 EBIT

GBP 550,000


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Inspiration Healthcare Group PLC is GBp34.00, about 83.8% above its October 26 closing price of GBp18.50


Reuters Recommended Reads

  • Oct 26 - UK's Computacenter raises profit forecast for fourth time this year, shares rise

  • Oct 26 - Senior doctors in England set to strike over pay offer in November

  • Oct 26 - GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Inspiration Healthcare

See all news